Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism

NCT06689085 is registered in ClinicalTrials.gov with Halozyme Therapeutics as lead sponsor.

NCT NCT06689085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06689085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism
Lead sponsor
Halozyme Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
March 7, 2025
Completion date
March 31, 2030
Enrollment
100 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hypogonadism, male